Skip to content

Enhancing extinction of conditioned sexual response by a partial NMDA receptors agonist.

Enhancing extinction of conditioned sexual response by a partial NMDA receptors agonist. - Enhancing extinction of conditioned sexual response

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON41206
Enrollment
68
Registered
2014-09-29
Start date
2014-10-06
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seksuele aandoeningen Hypersexuality Hyposexuality Sexual Motivation Disorders

Interventions

None listed

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age 45 years - Heterosexual orientation

Exclusion criteria

Exclusion criteria: - Pregnancy or lactation - Colour blindness - A diagnosis of affective, psychotic or substance related disorder according to DSM 5. - Current or recurrent use (less than 4 weeks before participation) of medication that may affect sexual response. To determine possible sexual side-effects the *Farmacotherapeutisch kompas* 2014 will be used. - Current or previous disorders of the genitals or treatments for such disorders that may influence the sexual response or the measurement of the response. - Other medical disorders that may influence the sexual response or the measurement of the response. - Current or recurrent use (less than 4 weeks before participation) of medication that may affect or interact with the effects of DCS. To determine possible contra-indications, instructions for use as supplied by *King Pharmaceuticals* will be used (see Appendix). - Current or previous disorders (like severe anxiety or psychosis, liver disease or severe renal insufficiency, epilepsy) that increase the possibility of side effects of DCS and for which usage of DCS is contra-indicated. - Alcohol or drug use on the night and day before participation, as well as alcohol and drug use between test moments (day 1 and day 2).

Design outcomes

Primary

MeasureTime frame
1) measures of vaginal pulse amplitude (VPA) assessed by a vaginal photoplethysmograph; 2) Subjective ratings of US expectancy, affective valence and sexual arousal

Secondary

MeasureTime frame
nvt

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)